Abstract Purpose: To describe the considerations leading to marketing approval of ixabepilone in combination with capecitabine and as monotherapy for the treatment of advanced breast cancer that is refractory to other chemotherapies. Experimental Design: Data from one randomized multicenter trial comparing combination therapy with ixabepilone and capecitabine to capecitabine alone were analyzed for support of the combination therapy indication. For monotherapy, a single-arm trial of ixabepilone was analyzed. Supporting data came from an additional single-arm combination therapy study and two singlearm monotherapy studies. Results: In patients with metastatic or locally advanced breast cancer who had disease progression on or following an anthracycline and a taxane, ixabepilone plus capecitabine showed an improvement in progression-free survival compared with capecitabine alone {median progression-free survival, 5.7 [95% confidence interval (95% CI), 4.8-6.7] versus 4.1 (95% CI, 3.1-4.3) months, stratified log-rank P < 0.0001; hazard ratio, 0.69 (95% CI, 0.58-0.83)}. As monotherapy for patients who had disease progression on or following an anthracycline, a taxane, and capecitabine, ixabepilone as monotherapy showed a 12% objective response rate by independent blinded review and 18% by investigator assessment.The major toxicities from ixabepilone therapy were peripheral neuropathy and myelosuppression, particularly neutropenia. Conclusions: On October 16, 2007, the Food and Drug Administration approved ixabepilone for injection in combination with capecitabine or as monotherapy for the treatment of patients with advanced breast cancer who have experienced disease progression on previous chemotherapies.
There will be an estimated 170,000 new cases of breast cancer diagnosed in the United States in 2007. A significant number of patients will require therapy for locally advanced or metastatic disease that has been diagnosed at presentation or has developed after prior treatment. Current chemotherapy for advanced breast cancer includes an anthracycline, usually doxorubicin or epirubicin, concurrently with or followed by a taxane, either paclitaxel or docetaxel. Anthracycline administration is often limited because of potential cardiomyopathic effects at higher cumulative doses. Patients who have disease that is resistant to these therapies, or who develop toxicities causing cessation, may then receive several agents that are of limited benefit. Although only capecitabine is approved in this specific setting, other agents including gemcitabine, vinorelbine, cisplatin, and carboplatin are also used. Standard therapy for patients with estrogen receptor (ER)-positive tumors includes either tamoxifen or an aromatase inhibitor depending on menopausal status. Patients with tumors overexpressing HER2 receive trastuzumab and also lapatinib after failure of trastuzumab.
Although the use of anthracyclines and taxanes has led to an increase in survival of patients with metastatic or locally advanced disease, the benefit from third-line therapies is less clear. Additionally, patients who receive adjuvant or neoadjuvant therapy at the time of initial diagnosis are often no longer able to receive further anthracycline or taxane therapy. Further development of effective therapies to treat patients with advanced breast cancer is clearly needed.
Disruption of microtubule function leads to apoptosis of dividing cancer cells, leading to cell death and tumor shrinkage. Ixabepilone, a type of epothilone, binds to tubulins in a manner distinct from that of other microtubule-binding agents, such as the taxanes, and leads to tubulin stabilization, which causes apoptosis (1) . Ixabepilone was shown to be active against tumors that were refractory to a taxane (2) . Similarly, toxicities with ixabepilone were expected to be similar to those seen with the taxanes, particularly peripheral neuropathy and myelosuppression. Clinical development of ixabepilone began in 1999. A multiarm dose-finding trial in combination with capecitabine established the dose to be used in the randomized trial comparing the combination with capecitabine alone. Monotherapy trials tested several doses of ixabepilone for use in breast cancer, and the final dose for both the monotherapy and combination therapy trials was determined to be 40 mg/m 2 administered over 3 h (3) . This development program provided the basis for the design and conduct of the clinical trials submitted for Food and Drug Administration (FDA) review.
Chemistry
Ixabepilone is a semisynthetic analogue of epothilone B, a 16-membered polyketide macrolide with a chemically modified lactam substitution for the naturally existing lactone. It has a molecular weight of 506.7 Da. Ixabepilone is a lyophilized white powder supplied with its polyethylated castor oil/ dehydrated alcohol diluent.
Preclinical Toxicology
Preclinical toxicology data included 6-month rat and 9-month dog studies. Ixabepilone principally affected tissues having rapid cell division, including the hematopoietic, gastrointestinal, and reproductive systems. The peripheral nerves were also a prominent site of toxicity at a greater extent in rats compared with dogs. Gastrointestinal toxicity included increased aspartate aminotransferase (AST), alanine aminotransferase (ALT), and decreased total protein, cholesterol, triglycerides, and albumin in high-dose animals. Also seen were degenerative changes in the gastrointestinal tract of rats, especially those that died in the study. Single-cell necrosis and reactive hyperplasia of the glandular mucosa were histologic changes observed in both rats and dogs. In addition, gastrointestinal toxicity characterized by red emesis and liquid stool, secondary dehydration, and gross discoloration was the cause of death in single-dose oral and i.v. studies in the dog.
Male reproductive organs, including the prostate/seminal vesicle, testes, and epididymis, showed decreased weight and were associated with atrophy in both rats and dogs. The rat study also showed female reproductive tract changes of atrophy of the uterine and vaginal epithelium. The atrophy and degeneration persisted during the 4-week recovery period.
Ixabepilone induced peripheral neuropathy in both rats and dogs. In severely affected rats that died during the study, axonal/myelin degeneration in the spinal cord, and cervical and lumbar dorsal root fibers was observed. Severe limb function impairment was also correlated with secondary atrophy and myofiber degeneration or necrosis in skeletal muscle in severely affected rats at the high dose.
Ixabepilone was not teratogenic in rat and rabbit studies. However, embryo-fetal toxicity was observed in both species. Carcinogenicity studies were not conducted with ixabepilone. Genotoxicity studies showed ixabepilone to be clastogenic in vivo in the rat micronucleus assay but not in vitro in the primary human lymphocyte assay. Ixabepilone was negative for mutagenicity in the Ames assay.
Clinical Pharmacology
The clinical pharmacology of ixabepilone was studied in patients with cancer. The peak plasma concentrations of ixabepilone typically occurred at the end of the 3-h infusion. Dose proportional increases in exposure were observed over the dose range of 15 to 57 mg/m 2 and the mean terminal half-life of ixabepilone was f52 h. The binding of ixabepilone to human plasma proteins in vitro ranged from 67% to 77% and the mean volume of distribution after a 40 mg/m 2 dose was in excess of 1,000 L. Following a single dose of radiolabeled ixabepilone, 65% was recovered in feces (1.6% intact parent) and 21% in urine (5.6% intact parent). Ixabepilone is extensively metabolized in the liver by cytochrome P450 3A4 (CYP3A4).
5 In vitro studies suggest that ixabepilone is not an inducer or inhibitor of human CYP enzymes; therefore, ixabepilone is not expected to alter the plasma concentrations of other drugs. There were no observed significant effects of patient age, gender, or race on ixabepilone pharmacokinetics.
Because ixabepilone is a substrate of CYP3A4, its exposure can be altered by inducers or inhibitors of CYP3A4.
5
Coadministration with the CYP3A4 inhibitor ketoconazole increased ixabepilone area under the curve by 79% compared with ixabepilone treatment alone. If a strong CYP3A4 inhibitor must be used, a lower dose of ixabepilone (20 mg/m 2 ) should be considered. There are no data currently available about the effects of CYP3A4 inducers on the pharmacokinetics of ixabepilone; however, caution should be used as the exposure of ixabepilone may decrease in the presence of CYP3A4 inducers. There was no clinically meaningful pharmacokinetic interaction seen in patients with cancer who received ixabepilone (40 mg/m 2 ) in combination with capecitabine (1,000 mg/m 2 ).
Ixabepilone doses of 10 to 40 mg/m 2 were evaluated in 56 patients with mild to severe hepatic impairment defined by bilirubin and AST levels. Compared with patients with normal hepatic function, the dose normalized area under the curve of ixabepilone increased by 22% in patients with mild hepatic impairment [bilirubin <1.5 Â upper limit of normal (ULN)]. For patients with moderate (bilirubin >1.5-3 Â ULN) and severe hepatic impairment (bilirubin >3 Â ULN), the dose normalized area under the curve increased 30% and 81%, respectively. Due to the increases seen in ixabepilone exposures, dose reductions are needed for patients receiving ixabepilone monotherapy who have bilirubin levels above the ULN and AST and ALT z2.5 Â ULN. Starting doses of 32 and 20 mg/m 2 are recommended for patients receiving ixabepilone monotherapy with mild and moderate hepatic impairment, respectively. Data were not conclusive to recommend a starting dose for patients with severe hepatic impairment; however, doses of 10 and 20 mg/m 2 were tolerated in 17 patients with severe hepatic impairment in the dedicated hepatic trial.
Based on safety findings, ixabepilone in combination with capecitabine is contraindicated in patients with AST or ALT >2.5 Â ULN or bilirubin >1 Â ULN. Patients receiving combination treatment who have AST and ALT V2.5 Â ULN and bilirubin V1 Â ULN may receive the standard dose of ixabepilone (40 mg/m 2 ). Because ixabepilone is minimally excreted via the kidney, no clinical study has been conducted in patients with compromised renal function. In a population pharmacokinetic analysis of ixabepilone administered as monotherapy, there was no meaningful effect of mild and moderate renal insufficiency (creatinine clearance, >30 mL/min).
Methods and Results

Review process
The completed New Drug Application seeking two indications was submitted on April 16, 2007 to the FDA. For the monotherapy indication, one study was done, with two supporting studies in similar populations. For the combination therapy indication, one study was done with an additional single-arm, dose-finding supporting study. On-site inspection of selected study sites in the United States and abroad was done by the FDA Division of Scientific Investigations.
Monotherapy
Study design. A single-arm, multicenter trial was conducted. Patients were women ages z18 years with histologically confirmed metastatic or locally advanced breast cancer who had previously received an anthracycline, a taxane, and capecitabine. Patients were required to have resistance to these therapies or, in the case of anthracyclines, received a maximum allowable dose. Progression while on trastuzumab or discontinuation of trastuzumab for toxicity was required for patients with tumors that overexpressed HER2. Patients were required to have at least one lesion evaluable by computerized tomography or magnetic resonance imaging. Adequate organ function and Karnofsky performance status z70 were required. If present, only peripheral neuropathy less than National Cancer Institute Common Toxicity Criteria for Adverse Events grade 2 was allowed. Patients were treated with 40 mg/m 2 ixabepilone as a 3-h infusion once every 3 weeks.
The primary end point was objective tumor response rate (ORR), consisting of partial responses and complete responses, determined radiologically and assessed once every 6 weeks. Response was determined by both an external independent radiological review committee (IRRC) and the individual investigators. Response Evaluation Criteria in Solid Tumors was used in determining response. Duration of response was calculated from time of determination of partial response or complete response to development of progressive disease. Time to response was calculated from the first day of therapy. The ORR was calculated along with the Clopper-Pearson 95% confidence interval (95% CI) for both the IRRC and investigator assessments. Patients lost to follow-up were censored on the date they were last known to be alive for survival analysis.
Results. One hundred and twenty-eight patients were enrolled in 36 centers in the United States, Canada, Latin America, and Europe, and 126 were treated with study drug. Data were collected between February 24, 2004 and database lock on December 21, 2005. Patient and disease characteristics are shown in Table 1 . The population studied had advanced disease, with 114 (90.5%) having disease at two or more metastatic sites. Patients had all received prior anthracycline, taxane, and capecitabine. Eighty-eight percent had received two or more prior regimens, and 49% had received three or more in the metastatic setting. Tumors were ER + in 47%, progesterone receptor -positive (PR + ) in 39%, HER2 + in 6%, and ER -, PR -, and HER2 -in 37%. Patients received a median of four cycles of ixabepilone, with discontinuation for disease progression in 93 (73.8%) and for toxicity in 27 (21.4%). Six (4.8%) patients discontinued therapy for other reasons.
Of 126 patients treated with ixabepilone, 113 were considered evaluable for response by the IRRC. Fourteen of 113 patients showed a partial response (Table 2 ). There were no complete responses identified. Investigator assessment of response identified 22 partial responses and 1 complete response in 126 treated patients. The potential reasons for the difference in response rates between investigator and IRC determination are addressed in Discussion.
Secondary end points of time to response and duration of response assessed by the IRRC are also summarized in Table 2 . Study design. The combination therapy trial was a randomized, multicenter, open-label study comparing ixabepilone plus capecitabine with capecitabine alone. Patients were women ages z18 years with histologically confirmed metastatic or locally advanced breast cancer. Patients were required to have received an anthracycline and a taxane and have progressive or resistant disease. Previous radiation therapy to <30% of bone marrow was acceptable. Patients with moderate or severe hepatic insufficiency (bilirubin >1 Â ULN or AST/ALT >2.5 Â ULN) were excluded from the trial after ongoing data review revealed an unacceptable mortality rate in this population. Other entry criteria were similar to the monotherapy trial.
The primary end point was progression-free survival (PFS), defined as time from randomization to radiologic progression, as determined by IRRC, or death from any cause. Clinical progression of measurable lesions was also allowed. Secondary end points included overall survival, ORR, duration of response, and time to response. Patients were randomized to treatment with either capecitabine alone at 2,500 mg/m 2 /d divided in two daily doses for 14 days or 40 mg/m 2 ixabepilone given once on day 1 along with 2,000 mg/m 2 /d capecitabine divided in two daily doses for 14 days starting on day 1. Each regimen was repeated every 3 weeks until disease progression or unacceptable toxicity.
Efficacy was evaluated every 6 weeks. In addition to computerized tomography or magnetic resonance imaging, ultrasound was allowed for superficial lesions, and skin lesions could be assessed by photograph and direct measurement with a ruler. Response Evaluation Criteria in Solid Tumors was used to determine response. The primary evaluation was done by the IRRC. PFS for a patient who did not progress or die was censored on the date of the last tumor assessment (as determined from the IRRC data). In addition, PFS for a patient who received subsequent therapy before progression or death was censored at the date of last assessment before the earliest start date of any subsequent therapy. Secondary end points were determined from the date of randomization or the date of response, as appropriate. Patients were required to have a confirmatory scan to be assessed as having a partial response or complete response.
Sample size of the study was calculated assuming an exponential PFS distribution in each group, with PFS a level adjusted for an interim analysis using the O'Brien-Fleming spending function. A total of 615 events were required for the final PFS analysis for a two-sided log-rank test at the a = 0.05 level to have 90% power to show a statistically significant difference when the hazard ratio was 0.77 (the assumptions were a median PFS of 3 months in the capecitabine group and a 30% greater median PFS in the ixabepilone plus capecitabine group).
The final analysis was done at a two-sided nominal significance level a = 0.0483 (adjusted for one interim analysis) to compare PFS between the two treatment arms using a logrank test stratified by presence of visceral metastases in liver and/or lung (yes, no), minimum of either 240 mg/m 2 doxorubicin or 360 mg/m 2 epirubicin and relapse >6 months in adjuvant setting (yes, no), and prior chemotherapy for metastatic disease (yes, no) as assigned at the time of randomization. The hazard ratio (ixabepilone + capecitabine compared with capecitabine) of PFS was estimated using a Cox proportional hazards model. PFS was estimated using KaplanMeier methods with a two-sided 95% CI. Survival is to be analyzed after 84% of the enrolled patients have died.
Results. Seven hundred fifty-two patients in 160 centers in 22 countries in North America, South America, Europe, and Asia were randomized. The study was initiated on September 4, 2003 and database lock occurred on December 1, 2006. Three hundred seventy-seven patients were randomized to capecitabine alone and 375 were randomized to the combination of ixabepilone and capecitabine (combination therapy). The characteristics of the patients enrolled in this study are shown in Table 3 . Ninety percent of patients in each arm had disease at two or more sites. The two arms were evenly balanced for hormone receptor expression, HER2 status, number of prior chemotherapies, race, and age. The patients enrolled in this trial were mostly White (67%) or Asian (23%). Patients in the combination arm received a median of five cycles of chemotherapy, whereas those in the capecitabine arm received a median of four cycles.
The combination of ixabepilone and capecitabine showed superiority over capecitabine monotherapy for the primary end point of PFS (Table 4) . Similar results were obtained with IRRC and with investigator assessments of progression. The data for overall survival were not mature at the time of submission of the New Drug Application. The objective response rate for the combination arm was superior to capecitabine monotherapy (Table 4) .
Safety. In the combination trial, there were a total of 39 patients in the capecitabine arm and 33 in the combination arm who died within 30 days of last dose. A total of 12 patients in the combination arm who died within 30 days were determined to have died due to study drug administration, whereas 2 in the capecitabine arm died due to capecitabine. Five of these 12 patients had moderate to severe hepatic insufficiency, and all died from complications of febrile neutropenia. Seven patients with normal hepatic function or mild impairment who received combination therapy died due to ixabepilone administration. Six of these cases seem to be related to febrile neutropenia, whereas the seventh may have had liver or cardiac toxicity as a contributory factor. Five additional deaths due to cardiopulmonary collapse may not be directly attributed to ixabepilone, but a causal relationship c Peripheral sensory neuropathy (graded with the National Cancer Institute Common Toxicity Criteria scale) was defined as the occurrence of any of the following: areflexia, burning sensation, dysesthesia, hyperesthesia, hypoesthesia, hyporeflexia, neuralgia, neuritis, neuropathy, neuropathy peripheral, neurotoxicity, painful response to normal stimuli, paresthesia, pallanesthesia, peripheral sensory neuropathy, polyneuropathy, polyneuropathy toxic, and sensorimotor disorder. Peripheral motor neuropathy was defined as the occurrence of any of the following: multifocal motor neuropathy, neuromuscular toxicity, peripheral motor neuropathy, and peripheral sensorimotor neuropathy. b Palmar-plantar erythrodysesthesia (hand-foot syndrome) was graded on a 1 to 3 severity scale in Study 046.
cannot be ruled out. One patient in the monotherapy study died with attribution to study drug. This patient who had had severe congestive heart failure at study entry died from febrile neutropenia.
The most significant toxicity shown during the use of ixabepilone either in monotherapy or in combination was peripheral neuropathy (Table 5 ). The overall rate of peripheral neuropathy was f65%. The neuropathy was primarily sensory, although motor neuropathy occurred in up to 16% of patients. The number of patients who experienced grade 3 or 4 neuropathy was up to 21%. In general, the neuropathy was reversible, with resolution to grade V1 in the majority of cases.
As would be expected, significant myelosuppression was observed in both the monotherapy and combination therapy trials, although the amount and extent observed in the combination therapy trial was greater (Table 6) . Grade 3 or 4 neutropenia occurred in 68% of patients receiving combination therapy and in 54% of patients receiving monotherapy. Other common but less serious adverse reactions included anorexia, asthenia, nausea, diarrhea, fatigue, alopecia, myalgias, and arthralgias. Of note, treatment with ixabepilone did not seem to increase the incidence of palmar-plantar erythrodysesthesia syndrome. Cardiac disorders, including arrhythmias and ischemia, were more frequent with ixabepilone, but the overall frequency remained low.
Discussion
Ixabepilone (Ixempra) was approved for marketing in the United States by the FDA for two indications. (a) Ixabepilone is indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. Anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting. Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting. (b) Ixabepilone is indicated as monotherapy for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine.
The FDA has relied on PFS for the approval of oncology drugs for some solid tumors.
6 For a drug to receive approval with this end point, the results must be shown convincingly in a trial that is both designed and executed carefully. The observed difference in PFS must be of clinical benefit and the results must be statistically sound. There must be a minimum of censoring due to patient dropouts and missing data. Finally, strategies such as blinding and the use of an independent, blinded review committee for adjudication that limit potential biases associated with use of PFS should be used. The randomized study met all of these criteria. The study was carefully designed to show a difference in PFS between capecitabine monotherapy and combination therapy. The primary PFS end point was properly defined as radiologic progression or death from any cause. Progression was determined by independent radiologists with no knowledge of the treatment group, which is an important consideration in reducing bias. The primary end point was met with convincing statistical significance. Secondary end points of investigator assessment of PFS, ORR, time to response, and response duration also support the primary finding. Of note, all sensitivity analyses done by either the sponsor or the FDA supported the finding of an advantage in PFS, suggesting that the result is robust across the entire population studied and not driven by a particular treatment group.
Ixabepilone was also approved for use as monotherapy in a similar patient population. Ixabepilone therapy was associated with durable responses. Although the patient population studied was one with advanced disease in whom multiple treatment options had failed, such patients are often still treated with other therapies, such as gemcitabine or navelbine. However, these therapies are associated with limited benefit and significant toxicity in this disease setting. In the current case, the convincing evidence of a benefit in PFS when used in combination with capecitabine, as well as the shown tumor responses in the monotherapy trial, supported the approval of ixabepilone for use as monotherapy in heavily pretreated patients with advanced breast cancer. There are significant safety concerns with the use of ixabepilone. Peripheral neuropathy is prevalent and can be severe. Of note, patients with grade z2 neuropathy at screening were excluded from participation in both studies. Patients who experienced neuropathy were generally able to recover with dose reduction or cessation, but it seems that the frequency and severity of neuropathy will limit the utility of ixabepilone therapy. Myelosuppression was also significant, particularly in combination with capecitabine. A protocol amendment enacted during the course of the combination therapy study limited enrollment to patients with elevations in liver function tests to at most grade 1 after an unacceptable increase in the number of deaths attributed to neutropenic fever was observed in patients with greater elevations. Because of the markedly increased incidence of death from febrile neutropenia in this population, the ixabepilone label contains a boxed warning cautioning against use in combination with capecitabine in patients with grade z2 elevations in liver function tests. The majority of patients (68%) receiving combination therapy experienced grade 3 or 4 neutropenia, and most deaths on study due to ixabepilone were from complications of febrile neutropenia. Although growth factors (granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor) were allowed on this study, their prophylactic use was not advised. The optimal prevention and management strategies for containing febrile neutropenia with ixabepilone therapy remain to be defined. A small number of patients receiving combination therapy had significant cardiac events, including arrhythmias and ischemia, which may be attributable to ixabepilone. The frequency was low, and the attribution was not definitive, but caution should be used in patients with a prior history of cardiac disease. Of note, all of the patients in this study had received an anthracycline, so that there may be a predisposition to cardiac toxicity. Further ongoing evaluation of the safety database for ixabepilone will identify whether this early signal is one that warrants further restriction or caution in the use of this drug. The other major adverse reactions with ixabepilone are generally manageable with current supportive measures and are generally not life threatening.
The applicant agreed to several postmarketing commitments, including the following: the submission of mature overall survival data from the submitted randomized trial, the submission of results of the ongoing randomized trial of somewhat similar design (ixabepilone plus capecitabine versus capecitabine) in a different patient population (metastatic breast cancer patients were not required to be taxane or anthracycline resistant or have met anthracycline cumulative dose requirements) and with a different primary end point of overall survival, the design and performance of a clinical trial to address any potential effects of ixabepilone on QT interval prolongation, a study to evaluate pharmacologic interaction with rifampin, and a study to determine if ixabepilone is a P-glycoprotein substrate or inhibitor. The approval of ixabepilone for use in breast cancer therapy shows that there is still a role for the development of cytotoxic drugs in cancer therapy. The difficulty in development and approval of such therapies lies in the significant toxicities observed due to biological effects in cells of normal tissue. Although the era of targeted therapies promises tumor inhibition with minimal effects on normal tissue, many such agents do not cause shrinkage of tumors and are unlikely to eradicate disease. Thus, there is still a need for more effective cytotoxic therapies to treat patients, especially those with advanced disease.
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